Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.45 |
| ▸ | DNER | Q8NFT8 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18979672 | 0.90 | BRD4 (0.46) | BRD4DNERADORA3TSPO | |
| SCHEMBL17165522 | 0.90 | BRD4 (0.46) | BRD4DNERADORA3TSPO | |
| SCHEMBL31498729 | 0.88 | BRD4 (0.45) | BRD4DNERADORA3TSPO | |
| SCHEMBL872054 | 0.87 | BRD4 (0.58) | BRD4DNERADORA3TSPO | |
| SCHEMBL18551067 | 0.87 | BRD4 (0.58) | BRD4DNERADORA3TSPO | |
| SCHEMBL19986334 | 0.84 | BRD4 (0.40) | BRD4DNERADORA3TSPO | |
| SCHEMBL23728703 | 0.84 | BRD4 (0.60) | BRD4DNERADORA3TSPO | |
| SCHEMBL30320662 | 0.84 | BRD4 (0.60) | BRD4DNERADORA3TSPO | |
| SCHEMBL17165553 | 0.82 | BRD4 (0.43) | BRD4DNERADORA3TSPO | |
| SCHEMBL17165549 | 0.82 | BRD4 (0.43) | BRD4DNERADORA3TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025085738-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | VHL, BRCA1, TP53 | BRD4 146/4885DNER 398/4885ADORA3 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.